1
|
Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 2020; 99:2903-2909. [PMID: 32583088 DOI: 10.1007/s00277-020-04158-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2019] [Accepted: 06/18/2020] [Indexed: 10/24/2022]
Abstract
From April 2016, carfilzomib, in combination with lenalidomide and dexamethasone (KRD), became available for use in the daily practice in Italy for patients with relapsed or refractory multiple myeloma (RRMM). We performed a retrospective survey at 14 different institutions from Southern Italy in order to evaluate patient characteristics and treatment results from an unselected series of patients treated accordingly so far. One hundred and twenty-three consecutive patients were included, with a median of 2 previous lines of therapy (range 1-9) and a median age of 63 years (range 39-82). At the time of analysis, median number of courses administered is 11 (range 1-34), and all patients are evaluable for response. Overall response rate including complete remission, very good partial remission, and partial remission is 85%. After a median follow-up of 27 months, median overall and progression-free survival are 33 and 23 months, respectively. Sixty-three patients are alive and between them, 45 (37%) are in continuous remission. Sixty patients have died (49%), mainly from progressive disease. There were 6 treatment-related deaths (5% of the whole patient population). Overall, hematological and non-hematological toxicity were manageable, mostly on outpatient basis. Arterial hypertension has been observed in 43 cases (35%) but did not lead to treatment interruption. Our data demonstrate that in real life, KRD is highly effective and well tolerated in the majority of patients with RRMM.
Collapse
Affiliation(s)
| | - S Rocco
- Hematology, "Cardarelli" Hospital, Naples, Italy
| | - O Vitagliano
- Hematology, "Cardarelli" Hospital, Naples, Italy
| | - L Catalano
- Hematology, AUOP "Federico II", Naples, Italy
| | - C Cerchione
- Hematology, AUOP "Federico II", Naples, Italy
| | - I D Vincelli
- Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
| | - A Scopelliti
- Hematology Unit, "Bianchi-Melacrino-Morelli" Hospital, Reggio Calabria, Italy
| | - M Gentile
- Onco-Hematology, Hematology Unit, AO of Cosenza, Italy
| | - G Farina
- Onco-Hematology, "S. Anna e S. Sebastiano" Hospital, Caserta, Italy
| | - M Barone
- Onco-Hematology, "Tortora" Hospital, Pagani, SA, Italy
| | - A Gagliardi
- Hematology, "Santa Maria di Loreto Nuovo" Hospital, Naples, Italy
| | - D Esposito
- Hematology, "San Giuseppe Moscati" Hospital, Aversa, CE, Italy
| | - M Arcamone
- Hematology/Oncology and SCT Unit, National Cancer Institute, Fondazione "Pascale", Naples, Italy
| | - V Amico
- Hematology, "Rummo" Hospital, Benevento, Italy
| | - R Fontana
- Hematology, AOU "Ruggi d'Aragona", Salerno, Italy
| | - A Sementa
- Hematology and SCT Unit, "San Giuseppe Moscati" Hospital, Avellino, Italy
| | - A Sica
- Onco-Hematology, AOU "Vanvitelli", Naples, Italy
| | - G Svanera
- Hematology, "San Giuliano" Hospital, Giugliano in Campania, Naples, Italy
| | - F Pane
- Hematology, AUOP "Federico II", Naples, Italy
| | - F Ferrara
- Hematology, "Cardarelli" Hospital, Naples, Italy
| |
Collapse
|
2
|
Rusconi C, Tucker D, Bernard S, Muzi C, Crucitti L, Stefani P, Cox M, Gini G, Re A, Sciarra R, Liberati A, Morello L, Arcari A, Mannina D, Vitagliano O, Sartori R, Chiappella A, Balzarotti M, Vitolo U, Thieblemont C, Rule S, Visco C. IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.54_2630] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- C. Rusconi
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - D. Tucker
- Department of Haematology; Royal Cornwall NHSTrust; Truro Cornwall United Kingdom
| | - S. Bernard
- Service d'Onco-Hématologie; Hôpital Saint-Louis, AP-HP; Paris France
| | - C. Muzi
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - L. Crucitti
- Division of Hematology; ASST Grande Ospedale Metropolitano Niguarda; Milan Italy
| | - P. Stefani
- U.O.C. di Ematologia; Dipartimento di Medicina Specialistica, Unità Locale Socio-Sanitaria della Marca Trevigiana; Treviso Italy
| | - M. Cox
- Haematology Unit, Department of Clinical and Experimental Medicine; Sapienza University, AO Sant'Andrea; Rome Italy
| | - G. Gini
- Division of Hematology; Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona; Ancona Italy
| | - A. Re
- U.O. Ematologia; Spedali Civili di Brescia; Brescia Italy
| | - R. Sciarra
- Division of Hematology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - A. Liberati
- Università di Perugia; AO Santa Maria di Terni; Terni Italy
| | - L. Morello
- Department of Medica Oncology and Hematology; Humanitas Clinical and Research Center - IRCCS; Rozzano Milan Italy
| | - A. Arcari
- Hematology Unit; Ospedale Guglielmo da Saliceto; Piacenza Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - O. Vitagliano
- Division of Hematology; Cardarelli Hospital; Naples Italy
| | - R. Sartori
- Hematology Department; Castelfranco Veneto Hospital, ULSS 2 Marca Trevigiana, Castelfranco Veneto; Treviso Italy
| | - A. Chiappella
- Hematology; AO Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Balzarotti
- Department of Medica Oncology and Hematology; Humanitas Clinical and Research Center - IRCCS; Rozzano Milan Italy
| | - U. Vitolo
- Hematology; AO Città della Salute e della Scienza di Torino; Turin Italy
| | - C. Thieblemont
- Service d'Onco-Hématologie; Hôpital Saint-Louis, AP-HP; Paris France
| | - S. Rule
- Plymouth University; Peninsula Schools of Medicine ad Dentistry; Plymouth United Kingdom
| | - C. Visco
- Department of Medicine; Section of Hematology, University of Verona; Verona Italy
| |
Collapse
|
3
|
Cerchione C, Vitagliano O, Della Pepa R, Cerciello G, Pareto A, Di Perna M, Soriente I, D’Arco A, Danise P, Alfinito F, Pane F. Management of Myelodysplastic Syndromes with Erythropoiesis Stimulating Agents (ESAS) in Real-Life Experience: An Update from Recamds. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30205-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Cerchione C, Vitagliano O, Simeone L, Pareto A, Soriente I, D'arco A, Danise P, Alfinito F, Pane F. 208 MANAGEMENT OF MYELODYSPLASTIC SYNDROMES WITH ERYTHROPOIESIS STIMULATING AGENTS: EVALUATION OF ERYTHROPOIETIC ASPECTS AND ANALYSIS OF RESPONSE. Leuk Res 2015. [DOI: 10.1016/s0145-2126(15)30209-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Danise P, Vitagliano O, Cerchione C, Soriente I, D'Arco A, Pane F, Alfinito F. P-165 Erythropoietic aspects in MDS patients responders to ESAs treatment. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70213-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
6
|
Cerchione C, Cerciello G, Pepa RD, Pugliese N, Marano L, Vitagliano O, Matarazzo M, Pane F, Alfinito F. P-187 Combination of deferasirox and deferoxamine in management of iron overload in myelodysplastic syndromes (MDS): An update in a hepatopatic patient. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70235-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|